These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33001144)

  • 21. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
    Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
    Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series.
    Sung J; Song A; Song M; Song J
    J Med Case Rep; 2022 Aug; 16(1):299. PubMed ID: 35927744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
    Bonini S; Lambiase A; Rama P; Sinigaglia F; Allegretti M; Chao W; Mantelli F;
    Ophthalmology; 2018 Sep; 125(9):1332-1343. PubMed ID: 29653858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
    Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
    JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasal decongestants in monotherapy for the common cold.
    Deckx L; De Sutter AI; Guo L; Mir NA; van Driel ML
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD009612. PubMed ID: 27748955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
    Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
    JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    Eichenfield LF; McFalda W; Brabec B; Siegfried E; Kwong P; McBride M; Rieger J; Willson C; Davidson M; Burnett P
    JAMA Dermatol; 2020 Dec; 156(12):1315-1323. PubMed ID: 32965495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
    Draelos ZD; Gold MH; Weiss RA; Baumann L; Grekin SK; Robinson DM; Kempers SE; Alvandi N; Weng E; Berk DR; Ahluwalia G
    J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxymetazoline in the treatment of allergic and non-infectious conjunctivitis.
    Fox SL; Samson CR; Danzig MR
    J Int Med Res; 1979; 7(6):528-30. PubMed ID: 391626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours.
    Druce HM; Ramsey DL; Karnati S; Carr AN
    Rhinology; 2018 Dec; 56(4):343-350. PubMed ID: 29785414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.